Stockreport

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Ce...

BioAtla, Inc.  (BCAB) 
PDF BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction. BioAtla will lead Phase 3 trial execution for Oz-V [Read more]